Live Breaking News & Updates on Lisah Lancaster

Stay updated with breaking news from Lisah lancaster. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pliant Therapeutics Inc. (PLRX) Presents Data from Bexotegrast Program

Pliant Therapeutics Inc. (PLRX) Presents Data from Bexotegrast Program
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United States , Christopher Keenan , Lisah Lancaster , American Thoracic Society , International Conference , European Medicines Agency , Pliant Therapeutics Inc , Drug Administration , Corporate Communications , Chief Medical Officer , Favorable Safety , Indicates Antifibrotic Activity , Idiopathic Pulmonary , Vanderbilt University Medical Center , With Standard Of Care Therapies Has , Synergistic Effect , Reducing Fibrogenic Gene Expression , Fibrotic Human Lung , Pathologic Fibroblasts , Human Fibrotic Lung Explant , Principal Scientist , Private Securities Litigation Reform Act , Pliant Therapeutics , Financial Condition , Annual Report , Quarterly Report ,

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

SOUTH SAN FRANCISCO, Calif., May 24, 2023 Pliant Therapeutics, Inc. , a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of. | June 11, 2023 ....

United States , Lisah Lancaster , Christopher Keenan , Pliant Therapeutics Inc , International Conference , Drug Administration , European Medicines Agency , American Thoracic Society , Corporate Communications , Chief Medical Officer , Vanderbilt University Medical Center , Principal Scientist , Private Securities Litigation Reform Act , Pliant Therapeutics , Financial Condition , Annual Report , Quarterly Report , Fast Track Designation , Orphan Drug Designation , Media Contact , Investor Relations ,

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative. | April 30, 2023 ....

Lisah Lancaster , Toby Maher , Christopher Keenan , Los Angeles , Drug Administration , Bexotegrast Clinical Development Next , University Of Southern California , Corporate Communications , Vanderbilt University Medical Center , Pliant Therapeutics Inc , European Medicines Agency , Group Demonstrated Treatment Effects Including Durable Improvements , Quantitative Lung Fibrosis , Well Tolerated , Percent Change , Cough Severity Visual Analog Scale , Baseline Over , Chief Medical Officer , Forced Vital Capacity , Idiopathic Pulmonary , Interstitial Lung Disease , Keck School , Southern California , Pliant Therapeutics , Private Securities Litigation Reform Act , Financial Condition ,

Pliant Therapeutics Announces Positive Long-Term Data from

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care. ....

Lisah Lancaster , Toby Maher , Los Angeles , Christopher Keenan , Group Demonstrated Treatment Effects Including Durable Improvements , Corporate Communications , Drug Administration , Vanderbilt University Medical Center , European Medicines Agency , Bexotegrast Clinical Development Next , Pliant Therapeutics Inc , University Of Southern California , Quantitative Lung Fibrosis , Well Tolerated , Percent Change , Cough Severity Visual Analog Scale , Baseline Over , Chief Medical Officer , Forced Vital Capacity , Idiopathic Pulmonary , Interstitial Lung Disease , Keck School , Southern California , Pliant Therapeutics , Private Securities Litigation Reform Act , Financial Condition ,

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative. | April 30, 2023 ....

Lisah Lancaster , Christopher Keenan , Los Angeles , Toby Maher , Drug Administration , Bexotegrast Clinical Development Next , Corporate Communications , Group Demonstrated Treatment Effects Including Durable Improvements , Keck School Of Medicine , Vanderbilt University Medical Center , University Of Southern California , Globenewswire Inc , Pliant Therapeutics Inc , European Medicines Agency , Quantitative Lung Fibrosis , Well Tolerated , Percent Change , Cough Severity Visual Analog Scale , Baseline Over , Chief Medical Officer , Forced Vital Capacity , Idiopathic Pulmonary , Interstitial Lung Disease , Southern California , Pliant Therapeutics , Private Securities Litigation Reform Act ,